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1 Introduction
Transfusion-acquired CMV infection in prema-
ture infants has been associated with significant
morbidity and mortality especially if the infant is
ill [1, 3, 10]. Pneumonia, hepatitis, thrombocyto-
penia and anemia associated with CMV infection
can compound the problem in infants who may
already have pulmonary, hepatic and marrow dys-
function resulting from prematurity per se and/or
superimposed diseases. The use of CMV seronega-
tive blood for transfusion in infants has been
shown to prevent transfusion acquired CMV in-
fection, but the logistics of obtaining CMV
seronegative blood products in a timely manner
for neonatal transfusions can be difficult [1, 11].
The purpose of this study was to determine the
efficacy of utilizing a prescreened CMV seronega-
tive blood donor program in preventing transfu-
sion acquired CMV infection in premature in-
fants.
2 Materials and methods
2.1 Populations
In northwest Ohio, the Regional Red Cross Blood
Center services three intensive care nurseries
(ICN) having a total of 85 beds. The total weekly
blood needs of the three ICN is twenty units of
blood collected in quint blood paks. The site of
the study was the ICN at The Toledo Hospital, a
level III regional neonatal center with 60 beds and
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660 admissions annually. This ICN received 10
units of blood every week for neonatal transfu-
sions during the study period.
2.2 Blood donors
Beginning in April, 1983, selected group 0 blood
donors who came to the Blood Center to donate
were screened for CMV antibody. The seronega-
tive donors were offered the opportunity to join
the "Baby Donor Club", which required a dona-
tion at least every four months and the availability
to come to the Blood Center when a donation
was requested. Re-screening of the donors was
performed every four months to validate their
seronegative status.
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2.3 Infants
The subjects of this study were infants with birth
weights less than 2000 g who were born between
July 1,1983 and April 30,1985 to CMV seronega-
tive mothers and received blood transfusions. Pro-
per informed consent was obtained from their
parents/guardians. CMV antibody status of the
infants was first determined by testing the cord
blood. CMV serology of the infant was then re-
peated at the time of the first transfusion, and
eight weeks after the first and last transfusions.
Likewise, a urine specimen for CMV culture was
also obtained at the time periods stated above.
As an environmental control, thirty term infants
with birth weights of less than 2000 g born of
CMV seronegative mothers, who resided in the
same nursery but did not receive blood transfu-
sions, were followed by urine cultures and serol-
ogy during the first week of life and eight weeks
after discharge.
2.4 Preparation of red blood cells
Blood was collected in a standard quint blood bag
with citrate-phosphate-dextrose-adenine (CPDA-
1) anticoagulant according to standard technique
[2]. The red blood cells prepared from the blood
had a hematocrit of 75%. A satellite bag was
often shared by several infants each day.
Fresh frozen plasma from group AB donors used
for the infants was obtained from random donors
whose CMV seroreactivity was not determined.
2.5 Virus isolation
Urine specimens pretreated with antibiotics were
cultured for CMV by inoculation into tubes of
human embryonic lung fibroblasts [8]. All cultures
were examined twice weekly for 4 weeks for the
appearance of typical focal CMV induced cyto-
phatic effect (CPE) and verified by specific immu-
nofluorescence when applicable.
2.6 CMV antibody screening
Initially, blood samples were screened for CMV
antibody using the Enzyme linked immuno-assay
Bio-Enza Bead (Litton Bionetics, Charleston, SC).
Beginning in January 1984, the interpretation of
the results was modified to consider individual
sample color variation. The changes were
prompted by a disconcordance of results with
parallel testing with the complement fixation (CF)
method. The results of evaluation of serology
techniques are published elsewhere [9].
Beginning in October 1984, the screening test was
performed using the CMV total antibody EIA
(Abbott Laboratories, Chicago, 111.).
3 Results
Five hundred and eighteen group 0 Rh positive
and 637 group 0 Rh negative donors were recru-
ited into the "Baby Donor Club" during the study
period. However, only 306 (26%) donors were still
in the Club at the end of the study. The high
attrition rate was due to relocation, loss of con-
tact, or inability to comply with the requisite of
availability and/or frequency of blood donation.
During the study period, 16 donors seroconverted,
a rate of 0.7% per annum.
One hundred twenty-seven of 183 (69%) of the
ICN admissions during the study period were
recruited into the study. These patients received
an average of 145 ml of blood from six donors in
eight transfusions. None of the CMV seronegative
infants who received CMV seronegative blood or
the control newborns showed clinical or labora-
tory evidence of CMV infection. However, six
units of CMV seropositive blood were given to 22
infants during the study period. These units were
mistakenly identified as CMV seronegative due to
technical errors or poor sensitivity of the test kit
in the initial phase of the study. Fifteen of these
22 infants were among the participants of our
study. One infant in the study group who was
born at 30 weeks gestation with a birth weight of
530 gm died at 4 weeks of age following complica-
tions of prematurity, gram negative sepsis, necro-
tizing enterocolitis and hyaline membrane disease.
This infant is not included in the statistical analy-
sis. Two of the remaining 14 infants developed
CMV infection as evidenced by seroconversion
and viruria after each received 15 ml of CMV
seropositive blood. However, six of these 14 in-
fants who also received aliquots of 10 to 24 ml
from the same units showed no serological or
culture evidence of CMV infection. During the
study period, another infant in the study group
acquired CMV infection through granulocyte
transfusions.
Comparing the infected and the uninfected infants
who received CMV seropositive RBC, there was
no significant difference with regard to age at
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transfusion, the number and amount of CMV
seropositive blood transfusions, the number of
seropositive donors, or the survival of the infants.
However, the birth weight of the uninfected group
(946 ±312 gm) was significantly lower than the
infected infants (1337 ± 222 gm) (p < 0.03).
In further analysis of the transfusion characteris-
tics of the three infants with transfusion acquired
CMV infection, we noted that two premature ba-
bies who required transfusions for anemia of im-
maturity had a single exposure to CMV seroposi-
tive RBC. One baby also received 103 ml of RBC
from six CMV seronegative donors, but each re-
ceived 15 ml of RBC from donors whose CF titers
of the CMV antibody were 8 and 32 respectively.
Seroconversion and viruria were noted eight
weeks after the last transfusion. Neither infant
had any symptoms attributable to CMV infection.
The third infant weighed 910 gm at birth and had
neutropenia and probable sepsis at 2 weeks of
age. In addition to 313 ml of RBC from 25 CMV
seronegative donors, he received four granulocyte
concentrations from three CMV seropositive do-
nors. CMV infection was noted eight weeks later
with interstitial pneumonia, deterioration of pul-
monary function, hepatitis and thrombocytope-
nia. The baby recovered without sequelae, but
had persistent viruria until the last urine culture
13 months after the granulocyte transfusions. The
CF titers of the granulocyte donors were 16, 32
and 32.
Sixteen units of blood were collected from
seroconverted donors. Fifteen units were not used
for infant transfusions as seroconversion was
found either before their release to the hospitals
or they were retrieved before use. One unit was
given to three infants in one to six transfusions.
Two infants were CMV seropositive on the cord
blood serology and were not included in the foll-
ow-up. The third was a 1 kg premature twin baby
whose cord blood was CMV seronegative. He
received 14 ml of RBC from the seroconverted
donor. On follow-up studies at four and eight
weeks post-transfusion, the infant remained CMV
seronegative and no viruria was detected.
During the study period, thirteen infants also re-
ceived fresh frozen plasma from as many donors
with an average of 64.8 ml (6-235 ml). The CMV
antibody status was available in six donors and
three of them were seropositive. None of the thir-
teen infants showed evidence of CMV infection.
4 Discussion
Our study indicates that the use of seronegative
red blood cells is highly successful in the preven-
tion of primary CMV infection in this susceptible
population. All CMV negative babies given CMV
seronegative blood remained uninfected. How-
ever, transfusion of CMV seropositive blood re-
sulted in CMV infection in 3 of 14 (21%) CMV
seronegative infants. As little as 15 ml of RBC
given in a single transfusion resulted in infection
in two of the babies. However, six babies who
received aliquots of blood from the same seroposi-
tive units did not develop clinical or laboratory
evidence of CMV infection. In reviewing the fac-
tors such as age, body weight, amount and the
number of CMV seropositive blood donors
exposed, which might have influenced the CMV
infectivity, only the body weight was statistically
different between the two groups. This finding
suggests that birth weight alone is not necessarily
a reliable indicator for susceptibility of CMV in-
fection.
Previous studies have emphasized the use of CMV
seronegative blood to prevent CMV infection [1,
11]. Results of other studies document the infectiv-
ity of granulocyte concentrates as well [6, 10]. In
contrast at least three of the infants who received
fresh frozen plasma obtained from CMV seroposi-
tive donors showed no evidence of CMV transmis-
sion in this study.
While availability and freshness are two prerequi-
sites of blood needs in neonatal transfusion, it is
a special challenge to the blood collecting agency
to meet these goals in an economical and efficient
manner. This study was designed to test a pre-
screening donor pool concept. During the study
period an adequate supply of less than five-day-
old blood was available for all three ICN. An
annual donor seroconversion rate of 0,7% is con-
sistent with other studies [4, 7]. While all 127
premature babies who participated in the study
received multiple blood transfusions, three infants
were exposed to CMV seropositive blood due to
seroconversion of a donor. One of these three
infants developed CMV infection which lead to
serious morbidity. A recent study suggested that
recently infected donors may transmit CMV more
efficiently than latent infected donors [5]. We find
it prudent that the prescreened blood be retested
before its use. Recently, a rapid latex agglutination
test has become available. Such testing allows us
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to recheck the CMV seronegative status of the
blood in a timely fashion prior to its release.
This test further expedites the availability of CMV
seronegative blood with minimal cost and delay.
This study indicates that a prescreened donor pool
is a sound medical and economical approach to
provide blood for premature infants for preven-
tion of transfusion-associated CMV infection.
Abstract
The purpose of this study was to evaluate the efficacy
of a prescreened CMV seronegative blood donor group
in preventing transfusion-acquired CMV infection in
premature infants in the perinatal period. Group 0 do-
nors with known CMV seronegative status were recru-
ited to supply blood to the neonatal intensive care
nurseries. One hundred and twenty-seven low birth
weight infants born of CMV seronegative mothers re-
mained seronegative when blood for transfusion was
screened for CMV antibody.
Twenty two infants shared six units of CMV seropositive
blood due to technical errors or poor sensitivity of the
test kit in the initial phase of the study. Fifteen of these
patients were in the study group. One infant died of
Keywords: Cytomegalovirus infection, transfusion.
immaturity at four weeks of age and two of the remain-
ing 14 showed asymptomatic CMV infection. Another
infant who received granulocyte concentrates from
CMV seropositive donors had symptomatic CMV infec-
tion.
Throughout the 24 month study period, blood supply
to the ICN was adequate and timely. The donor serocon-
version rate was 0.7% per annum. Only one infant was
exposed to the risk of CMV infection due to donor
seroconversion. We conclude that the prescreening do-
nor program is a sensible and efficient approach for
providing CMV seronegative blood in neonatal transfu-
sion therapy.
Zusammenfassung
Evaluierung eines Screenings auf Cytomegalievirus
(CMV) bei Blutspendern zur Prävention perinataler trans-
fusionsbedingter Infektionen
Untersucht wurde die Effizienz eines Screenings auf
CMV bei Blutspendern zur Prävention transfusionsbe-
dingter Infektionen bei Frühgeborenen in der Perinatal-
periode. Neonatale Intensivstationen wurden mit Blut
von Spendern mit der Blutgruppe 0 und bekanntem
CMV-seronegativen Status versorgt. 127 untergewich-
tige Neugeborene von CMV-seronegativen Müttern blie-
ben negativ, wenn die Transfundate auf CNfV-Antikör-
per getestet worden waren. \
22 Kinder erhielten CMV-seropositives Blut, was auf
technische Fehler oder eine zu geringe Sensitivität des
Test-Kits zu Beginn der Studie zurückzuführen war. 15
dieser Kinder waren in der Untersuchungsgruppe; davon
Schlüsselwörter: Cytomegalievirus, Transfusion.
starb eines wegen Unreife mit 4 Lebenswochen und
bei 2 Kindern kam es zur asymptomatischen CMV-
Infektion. Ein anderes Kind, das Granulozyten-Konzen-
trate von CMV-positiven Spendern erhalten hatte, ent-
wickelte eine CMV-Infektion mit Symptomatik.
Während der 24monatigen Untersuchungsperiode gab
es keine Engpässe oder zeitliche Verzögerungen bei der
Versorgung der Intensivstationen mit Blut. Die Serokon-
versionsrate bei den Spendern betrug 0.7% pro Jahr.
Lediglich ein Kind war wegen einer Konversion dem
Risiko einer CMV-Infektion ausgesetzt. Wir glauben,
daß das Screening der Spender auf CMV eine empfind-
liche und wirksame Methode ist, um für die neonatale
Transfusionstherapie CMV-seronegatives Blut bereit zu
haben.
Resume
Evaluation (Tun programme de pre-depistage chez les don-
neurs de sang dans le cadre de la prevention de l'infection
a cytomegalovirus (CMV) acquise par transfusion perina-
tale
Uobjectif de cette etude etait d'evaluer Fefficacite d'une
preselection d'un groupe de donneurs de sang CMV
seronegatifs pour prevenir l'infection ä CMV acquise
par transfusion chez les prematures en periode perina-
tale. On a recrute des donneurs du groupe 0, ayant une
CMV seronegative, pour les supplementations sanguines
des unites de spins intensifs neonataux (U. S. I. N.). Cent
vingt sept enfants de faible poids de naissance nes de
mere CMV seronegatives sont restes seronegatifs lorsque
le sang des transfusions avait subi la recherche d'anti-
corps anti CMV.
Vingt deux enfants se sont partages six unites de sang
CMV seropositifs du fait d'erreurs techniques ou d'une
faible sensibilite du kit dans la phase initiale de l'etude,
quinze de ces patients etaient dans le groupe etudie. Un
enfant est mort d'immaturite ä quatre semaines d'äge et
deux des 14 survivants ont presente une infection ä CMV
asymptomatique. Un autre enfant qui avait regu des
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concentres granulocytaires provenant de donneurs CMV
seropositifs a presente une infection ä CMV symptomati-
que.
Tout au long des 24 mois de la periode d'etude, Tapport
sanguin ä TU. S. I. N. a ete approprie et ä temps. Le
taux de seroconversion des donneurs est de 0,7% par
Mots-cles: Infection ä cytomegalovirus, transfusion.
an. Seul un enfant a ete expose au risque d'infection ä
CMV du fait d'une seroconversion d'un donneur. Nous
en concluons qu'un programme de pre-depistage des
donneurs est une approche sensible et efficace pour que
soit fourni du sang CMV seronegatif pour les transfu-
sions neonatales.
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